Johnny L. Raun
Kolding, Denmark
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry.
Journal: RMD open
Published: July 05, 2022
Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial.
Journal: Annals of the rheumatic diseases
Published: January 19, 2021
Hospital contacts due to hepatobiliary adverse events in >5000 patients with inflammatory joint disease treated with originator or biosimilar etanercept (SB4): an observational nationwide study applying linkage between DANBIO and national registries.
Journal: Annals of the rheumatic diseases
Published: November 25, 2019
Response to ''To switch or not to switch': the missing piece in the puzzle of biosimilar literature?' by Scherlinger et al.
Journal: Annals of the rheumatic diseases
Published: January 02, 2019
Response to: 'Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching' by Cantini and Benucci.
Journal: Annals of the rheumatic diseases
Published: December 04, 2018
Predictive value of a multi-biomarker disease activity score for clinical remission and radiographic progression in patients with early rheumatoid arthritis: a post-hoc study of the OPERA trial.
Journal: Scandinavian journal of rheumatology
Published: July 10, 2018
To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry.
Journal: Annals of the rheumatic diseases
Published: March 26, 2018
Validity and completeness of rheumatoid arthritis diagnoses in the nationwide DANBIO clinical register and the Danish National Patient Registry.
Journal: Clinical epidemiology
Published: December 15, 2017
Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry.
Journal: The Journal of rheumatology
Published: October 21, 2016
Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab-a substudy of the optimized treatment algorithm in early RA (OPERA) trial.
Journal: Clinical rheumatology
Published: August 15, 2016
Clinical and radiographic outcome of a treat-to-target strategy using methotrexate and intra-articular glucocorticoids with or without adalimumab induction: a 2-year investigator-initiated, double-blinded, randomised, controlled trial (OPERA).
Journal: Annals of the rheumatic diseases
Published: July 02, 2015
Prediction of treatment response to adalimumab: a double-blind placebo-controlled study of circulating microRNA in patients with early rheumatoid arthritis.
Journal: The pharmacogenomics journal
Published: October 22, 2014
Last Updated: 09/26/2026